Resverlogix Corp. · TSX:RVX

Resverlogix — Investor Presentation (December 2018)

31 slides from Resverlogix's investor presentation, December 2018

  1. Slide 1: Resverlogix Corp. Corporate Presentation

    TSX: RVX Resverlogix Corp. Corporate Presentation December, 2018

  2. Slide 2: Resverlogix at a Glance

    Resverlogix at a Glance Snapshot Profile • Late-stage clinical biotechnology company that has built a leadership position in epigenetics • Lead product candidate is Apabetalone, a first-in- class small molecule selective bromodomain Toronto Stock Exchange: extra-terminal (BET) protein inhibitor with

  3. Slide 3: Our Pipeline

    Our Pipeline Apabetalone Pre-clinical Phase 1 Phase 2 Phase 3 Status Est. Indication Initiation: 2015 Acute Coronary Trial completion Syndrome (ACS) estimate: H1 2019 Chronic Kidney Disease Initiation: H2 2019 Initiation: H2 2019 Fabry’s disease Pulmonary Arterial Initiation: H2 2019 Hypertension Va

  4. Slide 4: Addressing a Critical Unmet Need

    Addressing a Critical Unmet Need Cardiovascular disease The Diabetes Epidemic Cardiovascular disease is still the number one killer of both males and females and costs the US healthcare system over $500B per year Current CVD Therapies • Statins are the top medication used to treat CVD • Despite maxi

  5. Slide 5: Overview of Epigenetics

    Overview of Epigenetics • The epigenetic code refers to modifications to chromatin components that regulate its activity • Turning genes on or off is regulated by these modifications • BET (Bromodomain and Extraterminal Domain) proteins recognize these modifications and turn genes on TSX: RVX RESVER

  6. Slide 6: Our Differentiated BET Platform

    Our Differentiated BET Platform • Resverlogix has discovered compounds that selectively bind the bromodomains of BET proteins – Bromodomain selectivity: Resverlogix’s Apabetalone selectively targets BD2 – BET (BRD2, BRD3, BRD4) protein selectivity: Our expertise in medicinal chemistry and epigenetic

  7. Slide 7: Unique Mechanism of Action

    Unique Mechanism of Action Genome Editing The mechanism is based on cutting and pasting undesired/desired sequences into or out of the DNA, thereby altering the gene sequence and then re-introducing the modified DNA into the body. CRISPR – gene editing within a cell sub population Transcriptional Re

  8. Slide 8: Rationale for Kidney Disease Phase 2b/3

    Rationale for Kidney Disease Phase 2b/3 • Apabetalone has demonstrated reductions in alkaline phosphatase (a strong marker of CKD risk) and improvements in eGFR in CKD patients (eGFR < 60 mL/min/1.73m2) with CVD in the phase 2 ASSURE and SUSTAIN trials All Patients Patients With Baseline eGFR<60 mL/

  9. Slide 9: Kidney Disease Phase I Study

    Kidney Disease Phase I Study A Phase I, Open-Label, Parallel Group Study to Evaluate the Safety and Pharmacokinetics of a Single Oral Dose of Apabetalone in Subjects with Severe Renal Impairment Cohort 1 Previously diagnosed with CKD (stage IV) and not on dialysis (eGFR <30 mL/min/1.73m2) N=8 Apabet

  10. Slide 10: SOMAscan Analysis of Plasma Proteome in CKD Patients

    SOMAscan® Analysis of Plasma Proteome in CKD Patients IPA Canonical Pathways IL6 Signaling Dendritic cell maturation Th1 pathway NF-kB Signaling Acute Phase Response D>10% p≤0.05 Wasiak et al., 2017 TSX: RVX RESVERLOGIX.com 10

  11. Slide 11: SOMAscan Analysis of Plasma Proteome

    SOMAscan® Analysis of Plasma Proteome IPA Canonical Pathways: Top 5 Pathways Upregulated at Baseline IL6 Signaling Dendritic cell maturation Baseline Th1 pathway NF-kB Signaling Acute Phase Response D>10% p≤0.05 Wasiak et al., 2017 TSX: RVX RESVERLOGIX.com 11

  12. Slide 12: SOMAscan Analysis of Plasma Proteome

    SOMAscan® Analysis of Plasma Proteome IPA Canonical Pathways: Top 5 Pathways Downregulated with Apabetalone IL6 Signaling Dendritic cell maturation Apabetalone Th1 pathway NF-kB Signaling Acute Phase Response D>10% p≤0.05 Wasiak et al., 2017 TSX: RVX RESVERLOGIX.com 12

  13. Slide 13: SOMAscan Analysis of Plasma Proteome – Phase 1 Trial

    SOMAscan® Analysis of Plasma Proteome – Phase 1 Trial Apabetalone Reduces CVD and CKD Biomarkers Subjects with CKD (stage Matched Control IV) (n=8) treated with 100 Subjects (n=8) treated Gene mg Apabetalone with 100 mg Apabetalone Protein Name Symbol % D from baseline % D from baseline p-value p-va

  14. Slide 14: BET Inhibition Impacts Pathways Driving Cardiovascular and Kidney Diseases

    BET Inhibition Impacts the Pathways that Drive Cardiovascular Disease and Kidney Diseases Apabetalone, a bromodomain extra-terminal (BET) protein inhibitor, regulates the expression of genes and restores the function of pathways underlying the pathogenesis of CVD and kidney disease Reductions in the

  15. Slide 15: Critical Conclusions from our Phase 2 CVD Trials

    Critical Conclusions from our Phase 2 CVD Trials (ASSERT, ASSURE and SUSTAIN) Nicholls et al. 2018 Am J Cardiovasc Drugs Incidence of MACE in total patient group MACE in elevated CRP @ baseline subgroup Placebo (n=242) Placebo Elevated CRP (n=133) Apabetalone (n=556) Apabetalone Elevated CRP(n=290)

  16. Slide 16: BETonMACE Phase 3 Trial

    BETonMACE Phase 3 Trial Enrollment Complete; Trial completion expected H1 2019 2,400 + subjects atorvastatin Apabetalone 200mg daily + standard of care safety follow-up or • double blinded rosuvastatin • 1-2 week statin run-in run-in placebo + standard of care safety follow-up standard of care inclu

  17. Slide 17: Phase 3 BETonMACE

    Apabetalone Target Product Profile High Risk ACS with Diabetes and Low HDL-C High Risk Acute Coronary Syndrome (ACS) Patients with a Type II Diabetes Mellitus (DM) Comorbidity and Low High-Density Lipoprotein Cholesterol (HDL-C) • Time to the first occurrence of Major Adverse Cardiovascular Events (

  18. Slide 18: BETonMACE Commenced November 2015

    BETonMACE Commenced November 2015 UNITED RUSSIA POLAND STATES BELGIUM BULGARIA HUNGARY MEXICO SERBIA TAIWAN GERMANY CROATIA SLOVAKIA CROATIA ARGENTINA Apabetalone has already been tested in over 1,900 patients in 18 countries around the world, 14 countries have already approved Phase 3 usage TSX: RV

  19. Slide 19: Clinical Trial Analysis Points and Time Lines

    Clinical Trial Analysis Points and Time Lines 1 Maintain existing safety profile until trial completion, last dosing expected H1 2019 2 Adaptive trial options – stop dosing at 230-235 events and wait for 250 events or stop at 250 events and probably accumulate 270+ events? 4 Three point MACE event a

  20. Slide 20: Committee Members for BETonMACE

    Committee Members for BETonMACE Clinical Advisory Board Recent High Profile Publications Prof. Kausik K. Ray, BSc (hons), MBChB, MD, MPhil RVX-208, a BET-inhibitor for treating atherosclerotic (Cantab), FACC, FAHA, FESC, FRCP; cardiovascular disease, raises ApoA-I/HDL and represses pathways that con

  21. Slide 21: Our First Three Initial Opportunities

    Our First Three Initial Opportunities Top 8 Markets (U.S., Top 5 EU, Japan & Canada) Apabetalone is a first-in-class, small molecule that is a selective BET inhibitor that produces a specific set of biological effects with important benefits while maintaining a well described safety profile. It is c

  22. Slide 22: Additional Indications

    Additional Indications • Paroxysmal nocturnal hemoglobinuria – orphan indication • Neurofibromatosis – Malignant Peripheral Nerve Sheath Tumors (MPNST) orphan indication • Pulmonary Arterial Hypertension: orphan indication • Muscular Dystrophy/Facio Scapulo Humeral Dystrophy: orphan indication • Fab

  23. Slide 23: Business Development Strategy

    Business Development Strategy • Partnered Apabetalone in Greater China (China, Hong Kong, Taiwan and Macau) with Shenzhen Hepalink Pharmaceutical, a US$3.1 billion market cap company listed in China – US$35M initial equity investments in Resverlogix (total now exceeds US$100m) – >US$400M in projecte

  24. Slide 24: Management Team

    Management Team Donald McCaffrey Dr. Norman C.W. Wong, M.D., FRCP, A. Brad Cann, CA, Chief Financial President & Chief Executive Officer Chief Scientific Officer & Co Founder Officer • Co-founded Resverlogix in 2001 with • Co-founded Resverlogix in 2001 with • Has over 20 years of experience Dr. Nor

  25. Slide 25: Investment Highlights

    Investment Highlights 1 Global leader in epigenetic research and drug development 2 Apabetalone is a first-in-class BET inhibitor with potentially broad applicability across multiple disease indications 3 Addresses critical unmet need with 12 million+ patients in top 8 markets 4 Lead program has com

  26. Slide 26: Appendix

    Appendix

  27. Slide 27: Apabetalone Clinical Trials To Date

    Apabetalone Clinical Trials To Date Completed Trials Current and Planned Trials Phase 2 Phase 2b Phase 2b Phase 2b Phase 1 Phase 3 Phase 2a Phase 2a Phase 1a Phase 1 BE Phase 1 BE Phase 1b/2a ASSERT SUSTAIN ASSURE Pre-Diabetes PK Study BETonMACE Dialysis Fabry Disease n=80 n=7 n=9 n=72 n=299 n=176 n

  28. Slide 28: BET Literature Impact Growing CVD and Renal Risk

    BET Literature Impact Growing CVD and Renal Risk HDAC1/2 BRD4 P-TEFb Ac Ac TARGET Increase in GENE CVD and CKD RNA Pol II Risk Factors Adapted from: Campbell, AE. et al. 2017 Journal of Translational Cardiovascular Research on TSX: RVX RESVERLOGIX.com 28

  29. Slide 29: Recent High Profile Publications

    Recent High Profile Publications • Recent high profile publications illustrate apabetalone-induced activation of latent HIV-1 in vitro and ex vivo • Suggest that Apabetalone synergistically reactivated latent HIV-1 and could combine with cART drugs to inhibit viral infection TSX: RVX RESVERLOGIX.com

  30. Slide 30: BET Technology Goes Mainstream

    BET Technology Goes Mainstream TSX: RVX RESVERLOGIX.com 30

  31. Slide 31: Forward Looking Statement

    Forward Looking Statement This presentation may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends",

Resverlogix — Investor Presentation (December 2018) on 6ix